Star Therapeutics announces $125 million financing for VWD therapy
Biotechnology company Star Therapeutics has announced its $125 million Series D financing round was oversubscribed and will now initiate a clinical trial of its von Willebrand disease (VWD) therapy.
The financing round was co-led by Sanofi Ventures and Viking Global Investors, with participation from both existing and new investors, including Janus Henderson Investors, Frazier Life Sciences and GordonMD Global Investments. Existing investors include Agent Capital, Blue Owl Capital, Catalio Capital Management, Cormorant Asset Management, New Leaf Venture Partners, NYBC Ventures, OrbiMed, Qatar Investment Authority (QIA), RA Capital Management, Redmile Group, Sofinnova Investments, Soleus Capital and Westlake BioPartners.
Proceeds from the Series D financing will support the continued advancement of Star’s pipeline, including its lead programme, VGA039, a monoclonal antibody that targets Protein S to restore balance in blood clotting.
VGA039 is being developed as a universal haemostatic therapy for multiple bleeding disorders, starting with VWD. Star has initiated a Phase III clinical trial of VGA039 in patients with all types of VWD, designed to evaluate VGA039 administered once monthly via subcutaneous injection.
“We’re making significant progress across our pipeline, highlighted by the recent initiation of our Phase III trial of VGA039 to prevent bleeding in people with all types of VWD, the most common inherited bleeding disorder, with more than 50,000 patients diagnosed and treated in the US,” said Adam Rosenthal, CEO and Founder of Star Therapeutics.
“VGA039 has the potential to be transformative for VWD patients and could meaningfully reduce the treatment burden, given its once monthly subcutaneous dosing regimen, in comparison to factor replacement prophylaxis which requires two to three IV infusions per week.”
“This new funding from leading life sciences investors reinforces the urgency and impact of our mission: to bring life-changing therapies to people living with serious bleeding disorders and other diseases in haematology and immunology.”
Bruno Quinney, Content Team, DDW
